NCT03638791

Brief Summary

Background: Humans live in symbiosis with microbes and their implication for health and disease is evident. The importance of microbiome-gut-brain axis in psychiatric disorders is an area of increasing research interest. OCD is a promising target for microbiome research as Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)/ Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are reactions to infectious agents precipitating acute onset of severe OCD symptoms. Furthermore, preliminary evidence has associated probiotic treatment with alleviation of OCD symptoms. We propose the first clinical study on the microbiome and its effects on OCD patients. Aim: To analyze the gut microbiota in patients with OCD compared with healthy matched controls and assess changes in microbial composition following treatment. Outcome measures: Differences in alpha diversity, beta diversity, and taxa abundance of bacterial groups (at the phylum, class, order, family, genus and species levels) and severity of OCD symptoms. Moreover, functional profiling will be conducted. Methods: Our aim is to enroll 32 OCD patients and 32 matched controls. Shotgun metagenomic sequencing will be used. Sequenced data will be processed followed by non-parametric statistical testing. Significance: gut microbiome in patients with OCD beofre and after ERP treatment has never been done before. The microbial composition may impact on OCD symptoms, severity, and chronicity and could inform future therapeutic possibilities.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 16, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 20, 2018

Completed
4 months until next milestone

Study Start

First participant enrolled

December 5, 2018

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 4, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 4, 2022

Completed
Last Updated

September 21, 2022

Status Verified

September 1, 2022

Enrollment Period

3.8 years

First QC Date

August 16, 2018

Last Update Submit

September 19, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Alpha diversity

    expressed as number of observed species and Chao-1 estimator

    2018-09-01

Secondary Outcomes (3)

  • Beta diversity

    2018-09-01

  • Taxonomic and functional differences between cases and controls

    2018-09-01

  • Change in microtioba diversity before and after ERP treatment

    2018-09-01

Study Arms (2)

Healthy controls

Matched Controls without treatment

Behavioral: Exposure and response inhibition

OCD

Exposure and response inhibition

Behavioral: Exposure and response inhibition

Interventions

Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder

Healthy controlsOCD

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Recruitment of participants from Karolinska Hospital in Solna and Huddinge. Healthy Controls are recruited from Sweden from advertisements.

You may qualify if:

  • DSM-5 diagnosis of OCD. Age matched controls will be recruited who have no personal or family history of OCD.

You may not qualify if:

  • history of GI tract surgery (other than appendectomy or cholecystectomy); history of inflammatory bowel disease, irritable bowel syndrome, celiac disease, or any other diagnosis that could explain chronic or recurring bowel symptoms, antibiotic use in the past 3 months; pro-biotic use in the past 4 weeks; pregnancy. Intellectual disability, autism spectrum disorder and psychotic disorders.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M46: Karolinska Universitetssjukhuset, Psykiatri Sydväst

Stockholm, Huddinge, 141 86, Sweden

Location

Biospecimen

Retention: SAMPLES WITH DNA

Stool samples

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Condition Hierarchy (Ancestors)

Anxiety DisordersMental Disorders

Study Officials

  • Christian Rück, MD

    Karolinska Institutet

    STUDY CHAIR
  • Diana Radu Djurfeldt, MD

    Karolinska Institutet

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
4 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Rucklab, affiliate professor

Study Record Dates

First Submitted

August 16, 2018

First Posted

August 20, 2018

Study Start

December 5, 2018

Primary Completion

September 4, 2022

Study Completion

September 4, 2022

Last Updated

September 21, 2022

Record last verified: 2022-09

Locations